Literature DB >> 24277182

Pharmacokinetics of anthracyclines in dogs: evidence for structure-related body distribution and reduction to their hydroxy metabolites.

M J Oosterbaan1, R J Dirks, T B Vree, E van der Kleijn.   

Abstract

The pharmacokinetic disposition of the anthracyclines, adriamycin (doxorubicin), daunorubicin, 4'-epi-adriamycin, carminomycin, and 4-demethoxy-daunorubicin, and the formation of their reduced C13 hydroxy metabolites were studied in dogs. The presence of a C14hydroxy group (adriamycin and 4'epi-adriamycin) drastically reduces the appearance of the C13 hydroxy metabolites in plasma. Substitution of the C4-H with C4-OH and C4-OCH3, in this rank order, decreases the area under the plasma concentration-time curves of the parent compounds and their C13 hydroxy metabolites.

Entities:  

Year:  1984        PMID: 24277182     DOI: 10.1023/A:1016378609450

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  14 in total

1.  Cellular pharmocodynamics of several anthrocycline antibiotics.

Authors:  N R Bachur; M Steele; W D Meriwether; R C Hildebrand
Journal:  J Med Chem       Date:  1976-05       Impact factor: 7.446

2.  Adriamycin metabolism in man. Evidence from urinary metabolites.

Authors:  S Takanashi; N R Bachur
Journal:  Drug Metab Dispos       Date:  1976 Jan-Feb       Impact factor: 3.922

3.  Anthracycline derivatives in new drug development programs.

Authors:  M Rozencweig; C De Sloover; D D Von Hoff; H J Tagnon; F M Muggia
Journal:  Cancer Treat Rep       Date:  1979-05

4.  Significance of apparent half-lives of a metabolite with a higher elimination rate than its parent drug.

Authors:  T B Vree; C A Hekster; E van der Kleijn
Journal:  Drug Intell Clin Pharm       Date:  1982-02

Review 5.  The anthracycline antineoplastic drugs.

Authors:  R C Young; R F Ozols; C E Myers
Journal:  N Engl J Med       Date:  1981-07-16       Impact factor: 91.245

6.  The clinical evaluation of analogs--III. Anthracyclines.

Authors:  S K Carter
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

7.  Preliminary phase I study of 4'-epi-adriamycin.

Authors:  V Bonfante; G Bonadonna; F Villani; G Di Fronzo; A Martini; A M Casazza
Journal:  Cancer Treat Rep       Date:  1979-05

8.  Experimental evaluation of anthracycline analogs.

Authors:  A M Casazza
Journal:  Cancer Treat Rep       Date:  1979-05

9.  Structure-activity relationships among daunorubicin and adriamycin analogs.

Authors:  D W Henry
Journal:  Cancer Treat Rep       Date:  1979-05

10.  Anthracycline antibiotic pharmacology and metabolism.

Authors:  N R Bachur
Journal:  Cancer Treat Rep       Date:  1979-05
View more
  6 in total

1.  A comparison of regional versus systemic drug injection. Adriamycin concentration in peripheral blood and gastric stump (post-Billroth II gastrectomy) in the dog.

Authors:  F K P'eng; C W Wu; T J Chang; W Y Lui
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 2.  Clinical pharmacokinetics of doxorubicin.

Authors:  P A Speth; Q G van Hoesel; C Haanen
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

3.  Characterization of the Canine Anthracycline-Metabolizing Enzyme Carbonyl Reductase 1 (cbr1) and the Functional Isoform cbr1 V218.

Authors:  Daniel C Ferguson; Qiuying Cheng; Javier G Blanco
Journal:  Drug Metab Dispos       Date:  2015-04-27       Impact factor: 3.922

Review 4.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

5.  Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics in the dog.

Authors:  J R Baldwin; B A Phillips; S K Overmyer; N Z Hatfield; P K Narang
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Comparative metabolism and pharmacokinetics of doxorubicin and 4'-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice.

Authors:  W J van der Vijgh; P A Maessen; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.